Liver cirrhosis
Tóm tắt
Từ khóa
Tài liệu tham khảo
2011
D'Amico, 2006, Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies, J Hepatol, 44, 217, 10.1016/j.jhep.2005.10.013
Hytiroglou, 2012, Beyond “cirrhosis”: a proposal from the International Liver Pathology Study Group, Am J Clin Pathol, 137, 5, 10.1309/AJCP2T2OHTAPBTMP
Marcellin, 2013, Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study, Lancet, 381, 468, 10.1016/S0140-6736(12)61425-1
Morgan, 2010, Outcome of sustained virological responders with histologically advanced chronic hepatitis C, Hepatology, 52, 833, 10.1002/hep.23744
Garcia-Tsao, 2010, Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis, Hepatology, 51, 1445, 10.1002/hep.23478
Lozano, 2012, Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, 2095, 10.1016/S0140-6736(12)61728-0
Blachier, 2013, The burden of liver disease in Europe: a review of available epidemiological data, J Hepatol, 58, 593, 10.1016/j.jhep.2012.12.005
Hoyert, 2012, Deaths: preliminary data for 2011, Natl Vital Stat Rep, 61, 1
Wanless, 1995, Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension, Hepatology, 21, 1238
García-Pagán, 2012, Functional aspects on the pathophysiology of portal hypertension in cirrhosis, J Hepatol, 57, 458, 10.1016/j.jhep.2012.03.007
Cholongitas, 2006, Transjugular liver biopsy: how good is it for accurate histological interpretation?, Gut, 55, 1789, 10.1136/gut.2005.090415
Castera, 2012, Noninvasive methods to assess liver disease in patients with hepatitis B or C, Gastroenterology, 142, 1293, 10.1053/j.gastro.2012.02.017
Arvaniti, 2010, Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis, Gastroenterology, 139, 1246, 10.1053/j.gastro.2010.06.019
Fede, 2012, Renal failure and cirrhosis: a systematic review of mortality and prognosis, J Hepatol, 56, 810, 10.1016/j.jhep.2011.10.016
Moreau, 2013, Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis, Gastroenterology, 144, 1426, 10.1053/j.gastro.2013.02.042
Kim, 2012, The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis, J Hepatol, 57, 556, 10.1016/j.jhep.2012.04.029
Manousou, 2011, Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation, Liver Transpl, 17, 178, 10.1002/lt.22209
Parkes, 2010, Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease, Gut, 59, 1245, 10.1136/gut.2009.203166
Vergniol, 2011, Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C, Gastroenterology, 140, 1970, 10.1053/j.gastro.2011.02.058
Rein, 2012, The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings, Ann Intern Med, 156, 263, 10.7326/0003-4819-156-4-201202210-00378
Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496
Sheron, 2012, Developing a ‘traffic light’ test with potential for rational early diagnosis of liver fibrosis and cirrhosis in the community, Br J Gen Pract, 62, 616, 10.3399/bjgp12X654588
Roulot, 2011, Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years, Gut, 60, 977, 10.1136/gut.2010.221382
Tsochatzis, 2011, Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy, J Hepatol, 54, 650, 10.1016/j.jhep.2010.07.033
Naveau, 1997, Excess weight risk factor for alcoholic liver disease, Hepatology, 25, 108, 10.1002/hep.510250120
Tsochatzis, 2008, Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis, Aliment Pharmacol Ther, 27, 80, 10.1111/j.1365-2036.2007.03538.x
Berzigotti, 2011, Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis, Hepatology, 54, 555, 10.1002/hep.24418
Stepanova, 2010, Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study, Gut, 59, 1410, 10.1136/gut.2010.213553
Nkontchou, 2010, Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis, J Hepatol, 53, 827, 10.1016/j.jhep.2010.04.035
El-Serag, 2004, Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma, Gastroenterology, 126, 460, 10.1053/j.gastro.2003.10.065
Welzel, 2011, Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database, Hepatology, 54, 463, 10.1002/hep.24397
Plank, 2008, Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial, Hepatology, 48, 557, 10.1002/hep.22367
Luca, 1997, Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis, Gastroenterology, 112, 1284, 10.1016/S0016-5085(97)70142-2
2012, EASL clinical practical guidelines: management of alcoholic liver disease, J Hepatol, 57, 399, 10.1016/j.jhep.2012.04.004
Westin, 2002, Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection, J Viral Hepat, 9, 235, 10.1046/j.1365-2893.2002.00356.x
Ascha, 2010, The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, Hepatology, 51, 1972, 10.1002/hep.23527
Moriarty
Tsochatzis, 2012, New therapeutic paradigm for patients with cirrhosis, Hepatology, 56, 1983, 10.1002/hep.25915
Hézode, 2005, Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C, Hepatology, 42, 63, 10.1002/hep.20733
Leithead, 2008, Smoking-related morbidity and mortality following liver transplantation, Liver Transpl, 14, 1159, 10.1002/lt.21471
Freedman, 2012, Association of coffee drinking with total and cause-specific mortality, N Engl J Med, 366, 1891, 10.1056/NEJMoa1112010
Torres, 2013, Is it time to write a prescription for coffee? Coffee and liver disease, Gastroenterology, 144, 670, 10.1053/j.gastro.2013.02.015
Larsson, 2007, Coffee consumption and risk of liver cancer: a meta-analysis, Gastroenterology, 132, 1740, 10.1053/j.gastro.2007.03.044
De Gottardi, 2012, Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial, Am J Clin Nutr, 96, 584, 10.3945/ajcn.112.040469
Hernández-Guerra, 2006, Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension, Hepatology, 43, 485, 10.1002/hep.21080
Lewis, 2013, Review article: prescribing medications in patients with cirrhosis—a practical guide, Aliment Pharmacol Ther, 37, 1132, 10.1111/apt.12324
2012, EASL clinical practice guidelines: management of chronic hepatitis B virus infection, J Hepatol, 57, 167, 10.1016/j.jhep.2012.02.010
Manolakopoulos, 2009, Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension, J Hepatol, 51, 468, 10.1016/j.jhep.2009.05.031
Liaw, 2004, Lamivudine for patients with chronic hepatitis B and advanced liver disease, N Engl J Med, 351, 1521, 10.1056/NEJMoa033364
Everson, 2013, A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation, Hepatology, 57, 1752, 10.1002/hep.25976
McHutchison, 2009, Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection, N Engl J Med, 360, 1827, 10.1056/NEJMoa0806104
Poordad, 2011, Boceprevir for untreated chronic HCV genotype 1 infection, N Engl J Med, 364, 1195, 10.1056/NEJMoa1010494
Charlton, 2006, Impact of obesity on treatment of chronic hepatitis C, Hepatology, 43, 1177, 10.1002/hep.21239
Cholongitas, 2012, Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection, Aliment Pharmacol Ther, 35, 634, 10.1111/j.1365-2036.2012.05000.x
Rao, 2011, Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C, Gastroenterology, 140, 144, 10.1053/j.gastro.2010.08.055
Freedman, 2011, Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C, Gastroenterology, 140, 1961, 10.1053/j.gastro.2011.02.061
Burroughs, 2010, Hepatic venous pressure gradient in 2010: optimal measurement is key, Hepatology, 51, 1894, 10.1002/hep.23710
Groszmann, 2005, Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis, N Engl J Med, 353, 2254, 10.1056/NEJMoa044456
Ripoll, 2007, Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis, Gastroenterology, 133, 481, 10.1053/j.gastro.2007.05.024
Ripoll, 2009, Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis, J Hepatol, 50, 923, 10.1016/j.jhep.2009.01.014
de Franchis, 2010, Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension, J Hepatol, 53, 762, 10.1016/j.jhep.2010.06.004
Merli, 2003, Incidence and natural history of small esophageal varices in cirrhotic patients, J Hepatol, 38, 266, 10.1016/S0168-8278(02)00420-8
Garcia-Tsao, 2010, Management of varices and variceal hemorrhage in cirrhosis, N Engl J Med, 362, 823, 10.1056/NEJMra0901512
Gluud, 2007, Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials, Am J Gastroenterol, 102, 2842, 10.1111/j.1572-0241.2007.01564.x
Poynard, 1991, Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials, N Engl J Med, 324, 1532, 10.1056/NEJM199105303242202
Bosch, 1984, Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis, Hepatology, 4, 1200, 10.1002/hep.1840040617
Andreu, 2002, Total effective vascular compliance in patients with cirrhosis. Effects of propranolol, J Hepatol, 36, 356, 10.1016/S0168-8278(01)00300-2
Bosch, 2010, Carvedilol for portal hypertension in patients with cirrhosis, Hepatology, 51, 2214, 10.1002/hep.23689
Tripathi, 2009, Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed, Hepatology, 50, 825, 10.1002/hep.23045
Abraldes, 2003, Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis, Hepatology, 37, 902, 10.1053/jhep.2003.50133
Villanueva, 2009, Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding, Gastroenterology, 137, 119, 10.1053/j.gastro.2009.03.048
La Mura, 2009, Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension, J Hepatol, 51, 279, 10.1016/j.jhep.2009.04.015
Tandon, 2010, A specialized, nurse-run titration clinic: a feasible option for optimizing beta-blockade in non-clinical trial patients, Am J Gastroenterol, 105, 1917, 10.1038/ajg.2010.196
Burroughs, 2010, Primary prevention of variceal haemorrhage: a pharmacological approach, J Hepatol, 52, 946, 10.1016/j.jhep.2010.02.015
Abraldes, 2009, Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial, Gastroenterology, 136, 1651, 10.1053/j.gastro.2009.01.043
El-Serag, 2009, Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes, Gastroenterology, 136, 1601, 10.1053/j.gastro.2009.01.053
Lewis, 2007, Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial, Hepatology, 46, 1453, 10.1002/hep.21848
Bañares, 2002, Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis, Hepatology, 35, 609, 10.1053/jhep.2002.31354
Goulis, 1999, Bacterial infection in the pathogenesis of variceal bleeding, Lancet, 353, 139, 10.1016/S0140-6736(98)06020-6
Hou, 2004, Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial, Hepatology, 39, 746, 10.1002/hep.20126
Villanueva, 2013, Transfusion strategies for acute upper gastrointestinal bleeding, N Engl J Med, 368, 11, 10.1056/NEJMoa1211801
García-Pagán, 2010, Early use of TIPS in patients with cirrhosis and variceal bleeding, N Engl J Med, 362, 2370, 10.1056/NEJMoa0910102
Gonzalez, 2008, Meta-analysis: combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis, Ann Intern Med, 149, 109, 10.7326/0003-4819-149-2-200807150-00007
Wiest, 2002, The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough, Hepatology, 35, 478, 10.1053/jhep.2002.31432
Runyon, 2009, Management of adult patients with ascites due to cirrhosis: an update, Hepatology, 49, 2087, 10.1002/hep.22853
Hernández-Gea, 2012, Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers, Am J Gastroenterol, 107, 418, 10.1038/ajg.2011.456
Borzio, 2001, Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study, Dig Liver Dis, 33, 41, 10.1016/S1590-8658(01)80134-1
Angeli, 2010, Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial, Gut, 59, 98, 10.1136/gut.2008.176495
2010, EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis, J Hepatol, 53, 397, 10.1016/j.jhep.2010.05.004
Singh, 2012, Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study, J Hepatol, 56, 348, 10.1016/j.jhep.2011.04.027
Ginès, 1988, Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis, Gastroenterology, 94, 1493, 10.1016/0016-5085(88)90691-9
Salerno, 2007, Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data, Gastroenterology, 133, 825, 10.1053/j.gastro.2007.06.020
Bureau, 2011, Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS, J Hepatol, 54, 901, 10.1016/j.jhep.2010.08.025
Tandon, 2010, Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis, J Hepatol, 53, 273, 10.1016/j.jhep.2010.03.013
Vlachogiannakos, 2001, Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease, Gut, 49, 303, 10.1136/gut.49.2.303
Sersté, 2010, Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites, Hepatology, 52, 1017, 10.1002/hep.23775
Senzolo, 2011, Is hydrophobia necessary for the hepatologist prescribing nonselective beta-blockers in cirrhosis?, Hepatology, 53, 2149, 10.1002/hep.24176
Fernández, 2002, Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis, Hepatology, 35, 140, 10.1053/jhep.2002.30082
Thalheimer, 2005, Infection, coagulation, and variceal bleeding in cirrhosis, Gut, 54, 556, 10.1136/gut.2004.048181
Albillos, 2003, Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement, Hepatology, 37, 208, 10.1053/jhep.2003.50038
Nischalke, 2011, Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis, J Hepatol, 55, 1010, 10.1016/j.jhep.2011.02.022
Bellot, 2010, Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis, Hepatology, 52, 2044, 10.1002/hep.23918
Zapater, 2008, Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis, Hepatology, 48, 1924, 10.1002/hep.22564
Tritto, 2011, Evidence of neutrophil functional defect despite inflammation in stable cirrhosis, J Hepatol, 55, 574, 10.1016/j.jhep.2010.11.034
Coant, 2011, Glycogen synthase kinase 3 involvement in the excessive proinflammatory response to LPS in patients with decompensated cirrhosis, J Hepatol, 55, 784, 10.1016/j.jhep.2010.12.039
Senzolo, 2009, β-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis, Liver Int, 29, 1189, 10.1111/j.1478-3231.2009.02038.x
Reiberger, 2013, Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis, J Hepatol, 58, 911, 10.1016/j.jhep.2012.12.011
Worlicek, 2010, Splanchnic sympathectomy prevents translocation and spreading of E coli but not S aureus in liver cirrhosis, Gut, 59, 1127, 10.1136/gut.2009.185413
Rasaratnam, 2003, The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis: a randomized trial, Ann Intern Med, 139, 186, 10.7326/0003-4819-139-3-200308050-00008
Fernández, 2007, Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis, Gastroenterology, 133, 818, 10.1053/j.gastro.2007.06.065
Runyon, 1991, Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis: a randomized controlled study of 100 patients, Gastroenterology, 100, 1737, 10.1016/0016-5085(91)90677-D
Sort, 1999, Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis, N Engl J Med, 341, 403, 10.1056/NEJM199908053410603
Sigal, 2007, Restricted use of albumin for spontaneous bacterial peritonitis, Gut, 56, 597, 10.1136/gut.2006.113050
Guevara, 2012, Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis: a randomized, controlled study, J Hepatol, 57, 759, 10.1016/j.jhep.2012.06.013
Bajaj, 2009, Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites, Am J Gastroenterol, 104, 1130, 10.1038/ajg.2009.80
Bajaj, 2010, Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective, Am J Gastroenterol, 105, 106, 10.1038/ajg.2009.615
Jepsen, 2010, Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study, Hepatology, 51, 1675, 10.1002/hep.23500
Laleman, 2013, Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy, Hepatology, 57, 2448, 10.1002/hep.26314
Sharma, 2009, Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo, Gastroenterology, 137, 885, 10.1053/j.gastro.2009.05.056
Bai, 2013, l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials, J Gastroenterol Hepatol, 28, 783, 10.1111/jgh.12142
Bass, 2010, Rifaximin treatment in hepatic encephalopathy, N Engl J Med, 362, 1071, 10.1056/NEJMoa0907893
Bajaj, 2011, Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy, Gastroenterology, 140, 478, 10.1053/j.gastro.2010.08.061
Bajaj, 2012, Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis, Hepatology, 55, 1164, 10.1002/hep.25507
Soriano, 2012, Cognitive dysfunction in cirrhosis is associated with falls: a prospective study, Hepatology, 55, 1922, 10.1002/hep.25554
Davila, 2011, Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States, Ann Intern Med, 154, 85, 10.7326/0003-4819-154-2-201101180-00006
Tsochatzis, 2010, Prolonging survival in patients with cirrhosis: old drugs with new indications, Gastroenterology, 139, 1813, 10.1053/j.gastro.2010.10.031
Lisman, 2010, Hemostasis and thrombosis in patients with liver disease: the ups and downs, J Hepatol, 53, 362, 10.1016/j.jhep.2010.01.042
Tsochatzis, 2010, Systematic review: portal vein thrombosis in cirrhosis, Aliment Pharmacol Ther, 31, 366, 10.1111/j.1365-2036.2009.04182.x
Villa, 2012, Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis, Gastroenterology, 143, 1253, 10.1053/j.gastro.2012.07.018
Bellot, 2013, Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study, J Hepatol, 58, 922, 10.1016/j.jhep.2012.12.020
Vlachogiannakos, 2009, Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis, Aliment Pharmacol Ther, 29, 992, 10.1111/j.1365-2036.2009.03958.x
Kalambokis, 2012, Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites, Clin Gastroenterol Hepatol, 10, 815, 10.1016/j.cgh.2012.02.025
Nkontchou, 2011, Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients, J Clin Endocrinol Metab, 96, 2601, 10.1210/jc.2010-2415